|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:ATCCode
|
N02AA05
|
|
gptkbp:bioavailability_(oral)
|
60–87%
|
|
gptkbp:brand
|
gptkb:Endocet
gptkb:Percocet
gptkb:Roxicodone
gptkb:Targin
gptkb:OxyContin
|
|
gptkbp:CASNumber
|
76-42-6
|
|
gptkbp:chemicalFormula
|
C18H21NO4
|
|
gptkbp:combines
|
gptkb:ibuprofen
gptkb:aspirin
acetaminophen
|
|
gptkbp:controlled_substance
|
yes
|
|
gptkbp:discoveredBy
|
gptkb:Edmund_Speyer
gptkb:Martin_Freund
|
|
gptkbp:discoveredIn
|
1916
|
|
gptkbp:eliminationHalfLife
|
3–5 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:first_marketed
|
gptkb:Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oxycodone
|
|
gptkbp:IUPACName
|
(5R,9R,13S,14S)-14-hydroxy-3-methoxy-17-methyl-4,5-epoxymorphinan-6-one
|
|
gptkbp:KEGGID
|
D08362
|
|
gptkbp:legalStatus
|
gptkb:Schedule_II_controlled_substance
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
gptkb:noroxycodone
gptkb:oxymorphone
liver
|
|
gptkbp:molecularWeight
|
315.364 g/mol
|
|
gptkbp:pregnancyCategory
|
B
C
|
|
gptkbp:prescription_required
|
yes
|
|
gptkbp:produces
|
gptkb:thebaine
|
|
gptkbp:PubChem_CID
|
4447626
5284603
CHEMBL449
DB00497
|
|
gptkbp:relatedTo
|
gptkb:codeine
gptkb:morphine
gptkb:oxymorphone
hydrocodone
|
|
gptkbp:risk_of_withdrawal
|
yes
|
|
gptkbp:riskFactor
|
addiction
abuse
overdose
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
intravenous
rectal
|
|
gptkbp:sideEffect
|
nausea
constipation
itching
drowsiness
respiratory depression
|
|
gptkbp:UNII
|
C517H4A1WA
|
|
gptkbp:usedFor
|
moderate to severe pain
|
|
gptkbp:bfsParent
|
gptkb:Schedule_II
gptkb:Purdue_Pharma
gptkb:Schedule_II_(US)
|
|
gptkbp:bfsLayer
|
6
|